BIRC3 and B-cell chronic lymphocytic leukemia: CLL cells from JAK3006 also harbored an activating BIRC3 mutation that would be expected to facilitate non‐canonical NFκB signaling despite the presence of ibrutinib and ruxolitinib (Table 1).18